Success Story: Within 3 Months, NIW Approved for an Immuno-Oncology Researcher Advancing Cancer Treatment
Client’s Testimonial:
“Overall very happy with Chen team. I got a bit impatient with the time that the final review was taking, but I understand that is part of your high success rate! Team was very responsive and helpful along the way, instructions were extremely clear, and process was smooth in general.”
On September 8th, 2026, we received another EB-2 NIW (National Interest Waiver) approval for a Postdoctoral Researcher in the Field of Immuno-Oncology (Approval Notice).
General Field: Immuno-Oncology
Position at the Time of Case Filing: Postdoctoral Researcher
Country of Origin: Spain
State of Residence at the Time of Filing: Illinois
Approval Notice Date: September 8th, 2026
Processing Time: 2 months, 6 days (Premium Processing Requested)
Case Summary:
For patients with aggressive cancers, treatment remains particularly challenging because of factors such as tumor heterogeneity and resistance to existing therapies. The client’s proposed endeavor addressed this critical problem through advanced oncological research aimed at developing and evaluating highly targeted immunotherapies. By investigating complex tumor-associated mechanisms, the client sought to pioneer more effective cancer treatments, significantly improve patient survival rates, and resolve critical unmet clinical needs within modern oncology.
When North America Immigration Law Group (Chen Immigration Law Associates) prepared the NIW petition, the client brought an established record directly related to this endeavor. She held a Ph.D. in biology and had documented her research in 10 peer-reviewed journal articles and 6 conference abstracts. Her work had accumulated 247 citations, and she had also completed 1 peer review for a scientific journal.
Her work appeared in highly regarded journals spanning cancer research, cell biology, and related fields. NAILG also highlighted specific examples showing that independent researchers had relied on her findings to guide subsequent investigations into cancer immunotherapies, therapeutic targets, tumor progression, and molecular approaches to disease treatment.
The petition seamlessly connected the client's established influence with her prospective research. Her planned work involves developing and evaluating advanced immunotherapeutic strategies for highly aggressive, treatment-resistant cancers while investigating the complex biological mechanisms of these tumors. Because these malignancies are characterized by exceptionally high mortality and notoriously low survival rates, NAILG presented the endeavor not only as an extension of her specialized expertise, but as a critical response to vital U.S. interests in advanced oncology, public health, and biomedical innovation.
With a substantial body of published research already informing work by other scientists, the client is positioned to continue applying her immuno-oncology expertise to one of the most difficult areas of cancer treatment and to the broader search for more effective therapeutic approaches.